FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005562529> ?p ?o ?g. }

• W3005562529 endingPage "2170" @default.
• W3005562529 startingPage "2159" @default.
• W3005562529 abstract "Abstract Much of what is known about the neurotrophic receptor tyrosine kinase (NTRK) genes in cancer was revealed through identification and characterization of activating Trk fusions across many tumor types. A resurgence of interest in these receptors has emerged owing to the realization that they are promising therapeutic targets. The remarkable efficacy of pan-Trk inhibitors larotrectinib and entrectinib in clinical trials led to their accelerated, tissue-agnostic US Food and Drug Administration (FDA) approval for adult and pediatric patients with Trk-driven solid tumors. Despite our enhanced understanding of Trk biology in solid tumors, the importance of Trk signaling in hematological malignancies is underexplored and warrants further investigation. Herein, we describe mutations in NTRK2 and NTRK3 identified via deep sequencing of 185 patients with hematological malignancies. Ten patients contained a point mutation in NTRK2 or NTRK3; among these, we identified 9 unique point mutations. Of these 9 mutations, 4 were oncogenic (NTRK2A203T, NTRK2R458G, NTRK3E176D, and NTRK3L449F), determined via cytokine-independent cellular assays. Our data demonstrate that these mutations have transformative potential to promote downstream survival signaling and leukemogenesis. Specifically, the 3 mutations located within extracellular (ie, NTRK2A203T and NTRK3E176D) and transmembrane (ie, NTRK3L449F) domains increased receptor dimerization and cell-surface abundance. The fourth mutation, NTRK2R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical mechanisms that may involve altered interactions between the mutant receptor and lipids in the surrounding environment. Importantly, these 4 activating mutations can be clinically targeted using entrectinib. Our findings contribute to ongoing efforts to define the mutational landscape driving hematological malignancies and underscore the utility of FDA-approved Trk inhibitors for patients with aggressive Trk-driven leukemias." @default.
• W3005562529 created "2020-02-24" @default.
• W3005562529 creator A5005105433 @default.
• W3005562529 creator A5012556210 @default.
• W3005562529 creator A5014545118 @default.
• W3005562529 creator A5024181204 @default.
• W3005562529 creator A5033023115 @default.
• W3005562529 creator A5045185741 @default.
• W3005562529 creator A5056039766 @default.
• W3005562529 creator A5058340446 @default.
• W3005562529 creator A5061516412 @default.
• W3005562529 creator A5066373576 @default.
• W3005562529 creator A5068642524 @default.
• W3005562529 creator A5081773810 @default.
• W3005562529 date "2020-06-11" @default.
• W3005562529 modified "2023-10-14" @default.
• W3005562529 title "Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms" @default.
• W3005562529 cites W1496880511 @default.
• W3005562529 cites W1532766863 @default.
• W3005562529 cites W1803102843 @default.
• W3005562529 cites W1832172388 @default.
• W3005562529 cites W1938173378 @default.
• W3005562529 cites W1941281848 @default.
• W3005562529 cites W1965950769 @default.
• W3005562529 cites W1971147414 @default.
• W3005562529 cites W1976059757 @default.
• W3005562529 cites W1977926787 @default.
• W3005562529 cites W1983673751 @default.
• W3005562529 cites W1993870556 @default.
• W3005562529 cites W2000729091 @default.
• W3005562529 cites W2004377868 @default.
• W3005562529 cites W2005498869 @default.
• W3005562529 cites W2008603121 @default.
• W3005562529 cites W2008886334 @default.
• W3005562529 cites W2013472204 @default.
• W3005562529 cites W2026588006 @default.
• W3005562529 cites W2031591057 @default.
• W3005562529 cites W2038329478 @default.
• W3005562529 cites W2039616075 @default.
• W3005562529 cites W2041678991 @default.
• W3005562529 cites W2049507332 @default.
• W3005562529 cites W2053349906 @default.
• W3005562529 cites W2064378491 @default.
• W3005562529 cites W2065839571 @default.
• W3005562529 cites W2069671887 @default.
• W3005562529 cites W2082477555 @default.
• W3005562529 cites W2088757697 @default.
• W3005562529 cites W2089606003 @default.
• W3005562529 cites W2093585687 @default.
• W3005562529 cites W2098480759 @default.
• W3005562529 cites W2101466114 @default.
• W3005562529 cites W2106064593 @default.
• W3005562529 cites W2109269285 @default.
• W3005562529 cites W2110425545 @default.
• W3005562529 cites W2114083522 @default.
• W3005562529 cites W2115517051 @default.
• W3005562529 cites W2116999806 @default.
• W3005562529 cites W2118010975 @default.
• W3005562529 cites W2121635715 @default.
• W3005562529 cites W2124088653 @default.
• W3005562529 cites W2133013399 @default.
• W3005562529 cites W2138130369 @default.
• W3005562529 cites W2139565721 @default.
• W3005562529 cites W2145870089 @default.
• W3005562529 cites W2147209945 @default.
• W3005562529 cites W2148202982 @default.
• W3005562529 cites W2149290144 @default.
• W3005562529 cites W2149762420 @default.
• W3005562529 cites W2152770371 @default.
• W3005562529 cites W2153187042 @default.
• W3005562529 cites W2155046477 @default.
• W3005562529 cites W2172151766 @default.
• W3005562529 cites W2179484816 @default.
• W3005562529 cites W2256016639 @default.
• W3005562529 cites W2335155752 @default.
• W3005562529 cites W2342631118 @default.
• W3005562529 cites W2346877445 @default.
• W3005562529 cites W2398360333 @default.
• W3005562529 cites W2554580516 @default.
• W3005562529 cites W2586704604 @default.
• W3005562529 cites W2740079646 @default.
• W3005562529 cites W2766352488 @default.
• W3005562529 cites W2771786250 @default.
• W3005562529 cites W2790254562 @default.
• W3005562529 cites W2806450473 @default.
• W3005562529 cites W2808879139 @default.
• W3005562529 cites W2867213479 @default.
• W3005562529 cites W2885875860 @default.
• W3005562529 cites W2896424462 @default.
• W3005562529 cites W2900746171 @default.
• W3005562529 cites W2911070445 @default.
• W3005562529 cites W2942538710 @default.
• W3005562529 cites W2965739592 @default.
• W3005562529 cites W2977207635 @default.
• W3005562529 cites W4254604101 @default.
• W3005562529 doi "https://doi.org/10.1182/blood.2019003691" @default.
• W3005562529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7290093" @default.
• W3005562529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32315394" @default.

• next